Gastric Cancer News and Research

RSS

Study provides new data about potential risk of gastric cancer in patients with intestinal metaplasia

Gastric cancer remains a significant problem globally. The relationship between intestinal metaplasia (IM) and gastric cancer has always been controversial. Generally IM is divided into subtypes on the basis of histochemical characteristics; however, this classification is confusing.

10 Feb 2010

Data provide key information about epigenetic profiles for gastric cancer

Gastric cancer, one of the most common types of cancer, is associated with high mortality rates. In the last decades, a decrease in the worldwide incidence has been observed with some changes in the therapeutic and diagnostic options.

10 Feb 2010

MedCI forms new strategic alliance with Genta

MedCI LLC, a life-science business consulting services company, announced the formation of a new strategic alliance with Genta Incorporated to secure licensing partners for Genta’s small molecule oncology compound, tesetaxel.

28 Jan 2010

Researchers discover genetic variations that predict clinical outcomes in patients with stomach cancer

Researchers at the University of Southern California (USC) have, for the first time, identified specific genetic variations that predict clinical outcomes in patients with gastric (stomach) cancer.

22 Jan 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value.

22 Jan 2010

Epidemiologic characteristics of young age GC patients vary by age and gender

Two percent to fifteen percent of patients with gastric cancer (GC) are younger than 45 years of age and there has been an increase in the relative proportion of young age GC compared with older age GC, especially in young females.

20 Jan 2010

New research shows cutting tobacco smoking reduces cancer deaths in Europe

New research on deaths from cancer in Europe concludes that the key priority for continuing to reduce mortality is cutting tobacco smoking. The study shows that, while deaths for men from lung cancer in the EU have declined overall, by 17 % from 1995 to 2004, they rose by 27% for women over the same period.

17 Jan 2010

NetApp, Stanford Genome Technology Center build gastric cancer registry powered by NetApp storage technology

Gastric cancer is the number two cancer killer worldwide and one of the top cancer killers in the U.S., but gastric cancer research gets the least federal funding of any type of cancer research. According to a CBS News analysis of data released by the American Cancer Society, for every cancer-related death in the U.S., only $1,168 federal research dollars are spent on gastric cancer, versus $18,870 for cancer of the cervix and $14,095 for breast cancer.

12 Jan 2010

Study explains how H. pylori infection causes stomach cancer

Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer.

7 Jan 2010

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.

6 Jan 2010

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

New figures show steady decline in European cancer deaths, but variations exist between gender and countries

New figures show there was a steady decline in cancer deaths in the European Union between 1990-1994 and 2000-2004.

1 Dec 2009

Study on deaths from cancer in Europe shows steady decline in mortality

New figures on deaths from cancer in Europe show a steady decline in mortality between the periods 1990-1994 and 2000-2004. Deaths from all cancers in the European Union (EU) between these two periods fell by nine percent in men and eight percent in women, with a large drop among the middle-aged population.

29 Nov 2009

Erbitux drug can reverse rare stomach disorder, report researchers

A drug used to treat colorectal cancer also can reverse a rare stomach disorder and should be considered first-line therapy for the disease, researchers at Vanderbilt University Medical Center report this week.

25 Nov 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Gastric Cancer News and Research

Study provides new data about potential risk of gastric cancer in patients with intestinal metaplasia

Data provide key information about epigenetic profiles for gastric cancer

MedCI forms new strategic alliance with Genta

Researchers discover genetic variations that predict clinical outcomes in patients with stomach cancer

CytRx announces its plans to advance multiple oncology development programs in 2010

Epidemiologic characteristics of young age GC patients vary by age and gender

New research shows cutting tobacco smoking reduces cancer deaths in Europe

NetApp, Stanford Genome Technology Center build gastric cancer registry powered by NetApp storage technology

Study explains how H. pylori infection causes stomach cancer

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

New figures show steady decline in European cancer deaths, but variations exist between gender and countries

Study on deaths from cancer in Europe shows steady decline in mortality

Erbitux drug can reverse rare stomach disorder, report researchers

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Press conference highlights emerging treatments in pancreatic cancer

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News